ERBB2 and cervical cancer: Both UCC14-PDC (IC50 508.3 nM) and MGHU3 (an ERBB2 wildtype bladder cancer line, IC50 245.9 nM) were significantly less sensitive to neratinib as compared to CVX-437 (a HER2 S310F-mutant cervical cancer line, IC50 56.8 nM) and BT-474 (an ERBB2 amplified breast cancer cell line, IC50 0.1 nM)(Fig. 5c).